Abstract
Cardiovascular disease (CVD) is the leading cause of death in women and manifests more severely and at a later stage in life compared to men. The low estrogen levels during menopause are linked to an increased CVD risk. This association has promoted research regarding the role of hormone replacement therapy (HRT) in reducing the symptoms and diseases related to menopause, including CVD. This review article aims to discuss the biological changes associated with menopause and their impact on CVD. It also examines the effects of HRT in women with comorbidities related to CVD, its indications, risks, and contraindications.